AbbVie Bid for Biotech Could Expand with Experimental Drug
AbbVie is exploring a cash purchase of about $10.9 billion for a biotech developing an experimental eczema drug, a mo...
Uncover wealth-building strategies for the future. Take actionable steps today to secure your financial well-being.
20,267 articlesAbbVie is exploring a cash purchase of about $10.9 billion for a biotech developing an experimental eczema drug, a mo...
A biotech CEO just bought a sizable chunk of his company’s stock. That move sparks questions about conviction, risk, ...
GL Homes’ Riverland community demonstrates how interconnected design and amenities sustain sales momentum in a rising...
Space-focused investors have watched Redwire stock keep dropping as headlines swirl about contracts, funding, and exe...
Thailand confronts a high-stakes case that blends illegal crypto mining with money laundering. This article breaks do...
In volatile markets, investors seek safety. This guide compares gold, silver, bitcoin, and dividend stocks as safe ha...
Analysts see strong demand for Nvidia's AI hardware and software ecosystem. This piece breaks down why great news NVI...
Investors are weighing whether Chevron’s recent steps point to a new growth platform. This deep dive explains what a ...
A startup led by a former Apple engineer has secured $80 million to overhaul AI infrastructure for autonomous agents....
Regulators scrutinize exchange activity amid sanction challenges. This article breaks down CoinEx's denial, the fund ...
Strategy confronts a $12 billion unrealized loss on its bitcoin holdings as Bitcoin trades around $60,000, tightening...
Greece rolls out a four-satellite network that detects fires as small as four meters wide, aiming to cut wildfire los...